Loading…
Employees: 5
Size Indaptus Therapeutics (INDP) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $510M, the 2682nd largest of 3,117 United States companies the cockpit tracks. Shares closed at $3.32 on 6 Nov 2026.
Performance Over six months the shares gained 63.5%, against -18.1% for the median peer and -1.1% for the United States market (cap-weighted) — 3rd highest of 20 in its peer set.
Next results Next results expected around 17 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | $0 | $0 | -$735 | -$1,284 | -$1,781 |
| EBITDA | -$14.8M | -$19.8M | -$15.4M | -$16.4M | -$14.9M |
| Net income | -$15.4M | -$20.8M | -$15.0M | -$15.4M | -$14.3M |
| Free cash flow | -$15.8M | -$14.8M | -$12.3M | -$13.4M | -$13.1M |
| Capital expenditure | $0 | $0 | $0 | $0 | $0 |
| Total debt | $0 | $0 | $84,164 | $175,053 | $80,494 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | INDP | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +40.1% | -10.0% | highest of 21 |
| 6-month return | +63.5% | -18.1% | 3rd highest of 20 |
| Distance from 52-week high | -44.3% | -37.2% | 9th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Indaptus Therapeutics INDP | United States | $510M | +64% | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Yatai Pharmaceutical 002370.SZ | China | $514M | -32% | -4% | -11% | 9.8× | n/a | n/a |
| Gyre Therapeutics GYRE | United States | $505M | -36% | +17% | -11% | 4.1× | n/a | n/a |
| REGENXBIO RGNX | United States | $503M | -28% | +12% | -94% | 3.7× | n/a | n/a |
| Xiangxue Pharmaceutical 300147.SZ | China | $502M | -49% | +3% | -39% | 3.3× | 47.1% | -12.3% |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $519M | -18% | -4% | 18% | 4.0× | 6.7% | -4.1% |
| Hefei Lifeon Pharmaceutical 003020.SZ | China | $520M | -20% | -1% | 10% | 2.1× | n/a | n/a |
| Capricor Therapeutics CAPR | United States | $523M | -73% | -100% | n/a | n/a | n/a | n/a |
| Newland Pharmaceutical 301277.SZ | China | $523M | -22% | +9% | 11% | 3.9× | 10.2% | +9.1% |
| Gujarat Themis Biosyn GUJTHEM.NS | India | $524M | -5% | +18% | 39% | 28.5× | n/a | n/a |
| Cheng Du Sheng Nuo Biotec 688117.SS | China | $496M | -44% | +51% | 27% | 3.9× | 1.7% | +14.5% |
| Handa Pharmaceuticals 6620.TWO | Taiwan | $525M | +43% | +68% | 37% | 11.3× | 12.9% | +126.7% |
| SMS Pharmaceuticals SMSPHARMA.NS | India | $495M | +18% | +10% | 15% | 5.2× | n/a | n/a |
| Shanghai MicuRx Pharmaceutical 688373.SS | China | $495M | -16% | +23% | -61% | 19.6× | n/a | n/a |
| Egetis Therapeutics EGTX.ST | Sweden | $528M | +67% | +39% | -604% | 73.5× | n/a | n/a |
| Morepen Laboratories MOREPENLAB.NS | India | $529M | +110% | +30% | 11% | 2.2× | n/a | n/a |
| Boryung 003850.KS | South Korea | $531M | -14% | +6% | 6% | 0.7× | -8.9% | +12.6% |
| Electra Therapeutics ETRA | United States | $490M | n/a | n/a | n/a | n/a | n/a | n/a |
| PKU Healthcare 000788.SZ | China | $489M | -11% | -49% | 5% | 2.5× | -2.6% | -5.6% |
| Henan Taloph Pharmaceutical Stock 600222.SS | China | $533M | -5% | -5% | 7% | 2.7× | 17.7% | +4.4% |
| ChengDa PharmaCeuticals 301201.SZ | China | $535M | -43% | +27% | -9% | 5.7× | n/a | n/a |